BioLight agrees to sell ophthalmic laser specialist to Chinese firm

28 November 2017

Israeli ophthalmics specialist BioLight (TASE: BOLT) has announced that it has agreed to sell IOPtima, a developer of minimally-invasive surgical ophthalmic devices specializing in glaucoma, in which the firm has a majority stake.

BioLight, which owns about 70% of the company, has agreed terms together with the minority shareholders for the firm to be bought by Chengdu Kanghong Pharmaceutical Group, based in China.

The deal will be implemented in stages, the first stage being a direct investment into IOPtima of about $7 million, followed by an acquisition of the remaining IOPtima shares from all its other shareholders.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK